Skip to main content
SpringerLink
Log in

Primär- und Rezidivtherapie des Ovarialkarzinoms

Treatment of primary and recurrent ovarian cancer

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Da bis heute keine effektiven Screeningmaßnahmen etabliert sind, wird das Ovarialkarzinom in der überwiegenden Zahl der Fälle erst im fortgeschrittenen Stadium diagnostiziert. Während beim frühen Stadium nach adäquater Operation und Chemotherapie oft langfristige Heilungen möglich sind, erleiden die meisten Patientinnen mit einem weiter fortgeschrittenen Karzinom trotz maximaler Therapie ein Rezidiv. Beim so genannten platinrefraktären Rezidiv bringt eine Kombinationschemotherapie keine Vorteile im Vergleich zu einer Monotherapie. Beim platinsensiblen Rezidiv kann eine erneute operative Therapie mit dem Ziel der Komplettresektion des Tumors bei selektionierten Patientinnen sinnvoll sein. Platinhaltige Kombinationschemotherapien zeigten in diesem Kontext einen Vorteil gegenüber einer Monotherapie, zu beachten sind dabei allerdings die unterschiedlichen Toxizitätsprofile.

Abstract

In most cases, ovarian cancer is diagnosed at an advanced stage because effective screening procedures are lacking. After adequate surgery and chemotherapy, cure is often possible in early ovarian cancer. In advanced ovarian cancer, most patients will relapse despite maximum surgery and chemotherapy. Combination chemotherapy has no advantage compared with monotherapy in so-called platinum-refractory ovarian cancer. In platinum-sensitive recurrent ovarian cancer, secondary surgery with the aim of complete resection could be beneficial in selected patients. Platinum-based combination chemotherapies are superior to monotherapy in such patients. Different toxicity profiles must be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Bell J, Brady MF, Young RC et al. (2006) Randomised phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 102: 432–439

    Article  PubMed  CAS  Google Scholar 

  2. Burger RA, Sill MW, Monk BJ et al. (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 5165–5171

    Article  PubMed  CAS  Google Scholar 

  3. Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–1259

    Article  PubMed  Google Scholar 

  4. Bristow RE, Eisenhauer EL, Santillan A et al. (2007) Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 104: 480–490

    Article  PubMed  Google Scholar 

  5. Cannistra SA, Matulonis UA, Penson RT et al. (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180–5186

    Article  PubMed  CAS  Google Scholar 

  6. Du Bois A, Weber B, Rochon J et al. (2006) Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol 24: 1127–1135

    Article  CAS  Google Scholar 

  7. Du Bois A, Quinn M, Thigpen T et al. (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16 [Suppl 8]: VIII7–VIII12

  8. Ferrandina G, Ludovisi M, Lorusso D et al. (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26: 890–896

    Article  PubMed  CAS  Google Scholar 

  9. Garcia AA, Hirte H, Fleming G et al. (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26: 76–82

    Article  PubMed  CAS  Google Scholar 

  10. Gomez R, Harter P, Lück HJ et al. (in press) Int J Gynecol Cancer

  11. Gordon AN, Fleagle JT, Guthrie T et al. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312–3322

    PubMed  CAS  Google Scholar 

  12. Gore M, Du Bois A, Vergote I (2006) Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 24: 4528–4530

    Article  PubMed  Google Scholar 

  13. Harter P, Du Bois A, Hahman M et al. (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13: 1702–1710

    Article  PubMed  Google Scholar 

  14. Heintz AP, Odicino F, Maisonneuve P et al. (2006) Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet [Suppl 1] 95: 161–192

  15. Kandel M, Loehr A, Harter P et al. (2005) Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. Int J Gynecol Cancer 15: 780–784

    Article  PubMed  CAS  Google Scholar 

  16. Meier W, Du Bois A, Kuhn W et al. (2003) Topotecan vs treosulfan in recurrent ovarian cancer (OC) after initial therapy with platinum and paclitaxel. A prospective randomized phase III study. Proc Am Soc Clin Oncol 22: Abstract 1810

    Google Scholar 

  17. Mutch DG, Orlando M, Goss T et al. (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25: 2811–2818

    Article  PubMed  CAS  Google Scholar 

  18. Panici PB, Maggioni A, Hacker N et al. (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97: 560–566

    Article  PubMed  Google Scholar 

  19. Parmar MK, Lederman JA, Colombo N et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099–2106

    Article  PubMed  CAS  Google Scholar 

  20. Pfisterer J, Plante M, Vergote I et al. (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699–4707

    Article  PubMed  CAS  Google Scholar 

  21. Pfisterer J, Weber R, Reuss A et al. (2006) Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98: 1036–1045

    PubMed  CAS  Google Scholar 

  22. Scholz HS, Tasdemir H, Hunlich T et al. (2007) Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol 106: 591–595

    Article  PubMed  Google Scholar 

  23. Trimbos JB, Vergote I, Bolis G et al. (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organization for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95: 113–125

    PubMed  CAS  Google Scholar 

  24. Trimbos JB, Parmar M, Vergote I et al. (2003) International Collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95: 105–112

    PubMed  Google Scholar 

  25. Winter III WE, Maxwell GL, Tian CT et al. (2007) Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 25: 3621–3627

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie & Gynäkologische Onkologie, HSK, Dr. Horst Schmidt Klinik, Ludwig-Erhard-Straße 100, 65199, Wiesbaden, Deutschland

    P. Harter & A. du Bois

  2. Brust- und Tumorzentrum, Universitätskliniken für Frauenheilkunde und Medizinische Onkologie, Inselspital Bern, Bern, Schweiz

    S. Aebi

  3. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland

    F. Hilpert

Authors
  1. P. Harter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Aebi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Hilpert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. du Bois
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Harter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harter, P., Aebi, S., Hilpert, F. et al. Primär- und Rezidivtherapie des Ovarialkarzinoms. Onkologe 14, 1140–1150 (2008). https://doi.org/10.1007/s00761-008-1473-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-008-1473-3

Schlüsselwörter

Keywords

Search

Navigation